Evaluation of Urinary Isoprostanes in the Assessment of Children With Inflammatory Bowel Disease
Phase I Evaluation of Urinary Isoprostane Levels in Pediatric Patients With Inflammatory and Non-Inflammatory Gastrointestinal Disease
1 other identifier
observational
150
1 country
1
Brief Summary
Isoprostanes are compounds that are produced as a result of oxidative damage to cell membranes. Elevated tissue, serum, and urinary isoprostane levels have been described in a number of inflammatory diseases. The goal of this study is to determine utility of measuring urinary isoprostane levels in pediatric patients with inflammatory and non-inflammatory gastrointestinal disease. Urine samples will be collected from pediatric patients undergoing procedures in the Children's Hospital endoscopy unit. Clinical disease activity will be assessed using a standardized clinical disease activityiIndex. Gross endoscopic and histologic findings will be graded. Previously obtained laboratory studies will also be recorded. Urinary Isoprostane levels will be determined using a commercially available assay. Isoprostane levels will be compared across conditions (IBD vs. non-inflammatory, Crohn's disease vs. ulcerative colitis) and tested for statistical significance. Similarly, disease severity and urinary isoprostane levels will be assessed. The sensitivity, specificity, and positive and negative predictive values of elevated urinary isoprostane levels at discriminating pediatric patients with inflammatory and non-inflammatory gastrointestinal disease will be calculated.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Sep 2003
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2003
CompletedFirst Submitted
Initial submission to the registry
September 15, 2005
CompletedFirst Posted
Study publicly available on registry
September 22, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2006
CompletedJanuary 27, 2016
January 1, 2016
2.8 years
September 15, 2005
January 26, 2016
Conditions
Keywords
Eligibility Criteria
Patients with known or suspected IBD.
You may qualify if:
- Patients scheduled for endoscopic evaluation (upper endoscopy, colonoscopy or sigmoidoscopy)
- Patients currently completing lactose hydrogen breath tests (LHBT)
You may not qualify if:
- Patients with a previous history of HIV and/or chronic Hepatitis (or active acute hepatitis B or C). Patients will be asked about potential blood borne pathogens at the time of enrollment. No additional blood work or serologic testing outside that obtained for routine care will be required for participation in this study.
- Patients with a documented history of infectious diarrhea (within the past six months): Patients will be asked about previous testing for infectious diarrhea at the time of enrollment. When indicated, subjects will be asked to have primary care providers forward the results of previous testing.
- Patients with active Reactive Airway Disease (RAD)/Asthma.
- Patients with heart disease
- Smokers
- Patients with Connective tissue diseases (Scleroderma, Lupus, etc)
- Patients with Renal Disease
- Subjects must have had recent biochemical studies completed (including CBC, albumin, and ESR) within one month of receipt of sample.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Boston Children's Hospitallead
- Crohn's and Colitis Foundationcollaborator
Study Sites (1)
Children's Hospital
Boston, Massachusetts, 02115, United States
Biospecimen
Specimens stored at -80 in the Center for IBD at Boston Children's Hospital.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Paul A. Rufo, MD, MMSc
Boston Children's Hospital
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor of Pediatrics
Study Record Dates
First Submitted
September 15, 2005
First Posted
September 22, 2005
Study Start
September 1, 2003
Primary Completion
June 1, 2006
Study Completion
June 1, 2006
Last Updated
January 27, 2016
Record last verified: 2016-01
Data Sharing
- IPD Sharing
- Will not share